116 related articles for article (PubMed ID: 7561242)
1. Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients.
Pavlidis NA; Bairaktari E; Kalef-Ezra J; Nicolaides C; Seferiadis C; Fountzilas G
Int J Biol Markers; 1995; 10(2):75-80. PubMed ID: 7561242
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
3. High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer.
Barton DP; Blanchard DK; Michelini-Norris B; Nicosia SV; Cavanagh D; Djeu JY
Blood; 1993 Jan; 81(2):424-9. PubMed ID: 8422462
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
[TBL] [Abstract][Full Text] [Related]
5. Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients.
Hurteau JA; Simon HU; Kurman C; Rubin L; Mills GB
Am J Obstet Gynecol; 1994 Mar; 170(3):918-28. PubMed ID: 8141226
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
7. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.
Geisler JP; Miller GA; Lee TH; Harwood RM; Wiemann MC; Geisler HE
J Reprod Med; 1996 Mar; 41(3):140-2. PubMed ID: 8778409
[TBL] [Abstract][Full Text] [Related]
8. Soluble interleukin-2 receptors in patients with advanced colorectal carcinoma.
Pavlidis N; Nicolaides C; Bairaktari E; Kalef-Ezra J; Athanassiadis A; Seferiadis C; Fountzilas G
Int J Biol Markers; 1996; 11(1):6-11. PubMed ID: 8740635
[TBL] [Abstract][Full Text] [Related]
9. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Pavlidis AN; Kalef-Ezra J; Bourantas LC; Lambrou A; Mavridis A
Int J Biol Markers; 1993; 8(1):14-20. PubMed ID: 8496627
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer.
Scambia G; Testa U; Benedetti Panici P; Foti E; Martucci R; Gadducci A; Perillo A; Facchini V; Peschle C; Mancuso S
Br J Cancer; 1995 Feb; 71(2):354-6. PubMed ID: 7841052
[TBL] [Abstract][Full Text] [Related]
11. Clinical implication of serum sIL-2R levels in ovarian cancer.
Wang S; Cai G; Lu Y
J Tongji Med Univ; 1998; 18(2):126-8. PubMed ID: 10806842
[TBL] [Abstract][Full Text] [Related]
12. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
Elg SA; Hill RB; Heldman L; Ramakrishnan S
Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
[TBL] [Abstract][Full Text] [Related]
13. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
14. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.
Meisel M; Straube W; Weise J; Burkhardt B
Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
16. Soluble interleukin-2 receptors (sIL-2R) in ovarian cancer patients: changes in sIL-2R after surgery as a prognostic factor?
Gebauer G; Rieger M; Jäger W; Lang N
Int J Biol Markers; 1998; 13(1):45-7. PubMed ID: 9681299
[No Abstract] [Full Text] [Related]
17. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome.
Ambrosetti A; Nadali G; Vinante F; Carlini S; Veneri D; Todeschini G; Morosato L; de Sabata D; Chilosi M; Maggi E
Cancer; 1993 Jul; 72(1):201-6. PubMed ID: 8508408
[TBL] [Abstract][Full Text] [Related]
18. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer.
But I; Gorisek B
Gynecol Oncol; 1996 Nov; 63(2):166-72. PubMed ID: 8910622
[TBL] [Abstract][Full Text] [Related]
19. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
Naumnik W; Chyczewska E
Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 receptor and ovarian cancer.
Owens OJ; Taggart C; Wilson R; Walker JJ; McKillop JH; Kennedy JH
Br J Cancer; 1993 Aug; 68(2):364-7. PubMed ID: 8347492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]